RSS | Login | Register

Kapidex to be marketed under new trade name Dexilant

March 04, 2010

Print
Email
Reprint
Permissions
Font Size: A | A | A

RELATED CONDITIONS

Hyperacidity, GERD, and ulcers

Takeda Pharmaceuticals announced that Kapidex (dexlansoprazole delayed-release capsules) will now be marketed under a new product trade name, Dexilant, due to reports of dispensing errors. Takeda and the FDA have received reports of dispensing errors between Kapidex and Casodex (bicalutamide tablets, from AstraZeneca) and have determined a name change would be the best way to minimize future medication errors. The formulation, indication, and approved dosages of Dexilant will remain the same as Kapidex. Markings on the capsules and the capsule appearance will be identical to capsules marketed under the Kapidex trade name.

Kapidex, now Dexilant, is indicated for the treatment of erosive esophagitis (EE) and heartburn related to non- erosive gastroesophageal reflux disease (GERD) as well as the maintenance of healing of EE.

For more information call (877) TAKEDA-7 or visit www.tpna.com.

| Share

Phase 2 study of TZP-102 for diabetic gastroparesis

June 29, 2010

Tranzyme Pharma announced positive results from its Phase 2 study of TZP-102 for the treatment of gastroparesis in patients with diabetes mellitus (DM).

NDA submitted for Xifaxan for treatment of non-constipation irritable bowel syndrome

June 08, 2010

Salix Pharmaceuticals announced that a New Drug Application (NDA) has been submitted to the FDA seeking approval of Xifaxan (rifaximin 550 mg tablets) for the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS) and IBS-related bloating.

FDA accepts NDA for Duexa for ulcer risk reduction in arthritis patients

May 26, 2010

Horizon Pharma announced that its New Drug Application (NDA) for Duexa was accepted by the FDA for the reduction of the risk of development of upper gastrointestinal ulcers in patients with arthritis and pain.

Proton pump inhibitors (PPIs) class labeling change to include fracture risk

May 26, 2010

The FDA has notified healthcare professionals and patients of labeling changes for prescription and over-the-counter (OTC) proton pump inhibitors (PPIs) to include new safety information about a possible increased risk of fractures with the use of these medications.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.